Solid Biosciences to Participate at the Jefferies Global Healthcare Conference
Rhea-AI Summary
Solid Biosciences (NASDAQ: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, announced its participation in the upcoming Jefferies Global Healthcare Conference. President and CEO Bo Cumbo and Chief Medical Officer Gabriel Brooks will engage in a fireside chat on June 4, 2025, at 2:00 pm ET. The presentation will be accessible via live webcast on the company's website's Investor Events page, with a replay available for 30 days afterward. Institutional investors can arrange meetings with management through their Jefferies representatives.
Positive
- None.
Negative
- None.
News Market Reaction – SLDB
On the day this news was published, SLDB gained 7.24%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CHARLESTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, at 2:00 pm ET.
A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conference may reach out to their Jefferies representative.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
When is Solid Biosciences (SLDB) presenting at the Jefferies Global Healthcare Conference 2025?
Who will represent Solid Biosciences (SLDB) at the Jefferies Healthcare Conference?
How can investors access Solid Biosciences' (SLDB) presentation at the Jefferies Conference?
What type of medicines does Solid Biosciences (SLDB) develop?
